- Home
- XBIT
XBIT
XBiotech Inc.
as 05-30-2025 4:00pm EST
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 105.2M | IPO Year: | 2015 |
| Target Price: | N/A | AVG Volume (30 days): | 47.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.65 - $8.32 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest XBiotech Inc. News
XBIT Breaking Stock News: Dive into XBIT Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 days ago
Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation
Associated Press Finance
17 days ago
XBiotech: Q1 Earnings Snapshot
Simply Wall St.
5 months ago
XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35%
MT Newswires
5 months ago
XBiotech Pauses Rheumatology Clinical Program Due to Irregularities in Phase II Natrunix Study; Shares Fall
GlobeNewswire
5 months ago
XBiotech Pauses Rheumatology program
Associated Press Finance
10 months ago
XBiotech: Q2 Earnings Snapshot
GlobeNewswire
a year ago
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Associated Press Finance
a year ago
XBiotech: Q1 Earnings Snapshot
Compare XBIT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XBIT XBiotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.